Targeting Neuroinflammation in Brain Cancer: Uncovering Mechanisms, Pharmacological Targets, and Neuropharmaceutical Developments.
Mahmoud S. Alghamri,Brandon L. McClellan,Margaret S. Hartlage,Santiago Haase,Syed M Faisal,Rohit Thalla,Ali Dabaja,Kaushik Banerjee,Stephen Carney,Anzar A. Mujeeb,Michael R. Olin,James J. Moon,Anna Schwendeman,Pedro R. Lowenstein,Maria G. Castro +14 more
Reads0
Chats0
TLDR
Glioblastomas are one of the most lethal types of cancers accounting for ~80% of all central nervous system (CNS) primary malignancies [1, as discussed by the authors.Abstract:
Gliomas are one of the most lethal types of cancers accounting for ~80% of all central nervous system (CNS) primary malignancies [1; 2]. Amongst gliomas, glioblastomas (GBM) are the most aggressive, characterized by a median patient survival of fewer than 15 months. Recent molecular characterization studies uncovered the genetic signatures and methylation status of gliomas and correlate these with clinical prognosis [2]. The most relevant molecular characteristics for the new glioma classification are IDH mutation, chromosome 1p/19q deletion, histone mutations, and other genetic parameters such as ATRX loss, TP53, and TERT mutations, as well as DNA methylation levels. Similar to other solid tumors, glioma progression is impacted by the complex interactions between the tumor cells and immune cells within the tumor microenvironment. The immune system’s response to cancer can impact the glioma’s survival, proliferation, and invasiveness. Salient characteristics of gliomas include enhanced vascularization, stimulation of a hypoxic tumor microenvironment, increased oxidative stress, and an immune suppressive milieu. These processes promote the neuro-inflammatory tumor microenvironment which can lead to the loss of blood-brain barrier (BBB) integrity. The consequences of a compromised BBB are deleteriously exposing the brain to potentially harmful concentrations of substances from the peripheral circulation, adversely affecting neuronal signaling, and abnormal immune cell infiltration; all of which can lead to disruption of brain homeostasis. In this review, we first describe the unique features of inflammation in CNS tumors. We then discuss the mechanisms of tumor-initiating neuro-inflammatory microenvironment and its impact on tumor invasion and progression. Finally, we also discuss potential pharmacological interventions that can be used to target neuro-inflammation in gliomas.read more
Citations
More filters
Journal ArticleDOI
RNA binding by ADAR3 inhibits adenosine-to-inosine editing and promotes expression of immune response protein MAVS
Reshma Raghava Kurup,Eimile Oakes,Aidan C. Manning,Priyanka Mukherjee,Pranathi Vadlamani,Heather A. Hundley +5 more
TL;DR: In this article , a global view of ADAR3-bound RNAs in glioblastoma cells and identifies both a role for ADAR-3 in repressing ADAR1-mediated editing and an RNA-binding dependent function of adar3 in regulating MAVS expression.
Journal ArticleDOI
Neuroinflammation and immunoregulation in glioblastoma and brain metastases: Recent developments in imaging approaches.
TL;DR: In this article, a review of recent advances in imaging methods that have helped to improve the specificity of primary tumor diagnosis versus evaluation of inflamed and necrotic brain lesions is presented.
Journal ArticleDOI
Dopamine, Immunity, and Disease
Breana Channer,Stephanie M. Matt,E. A. Nickoloff-Bybel,Vassiliki Pappa,Yash Agarwal,Jason R Wickman,Peter J. Gaskill +6 more
TL;DR: In this article , a review comprehensively assesses the current knowledge of dopaminergic immunology at the cellular, tissue, and disease level and prompts the development of therapeutics and strategies targeted toward ameliorating disease through dopamine regulation of immunity.
Journal ArticleDOI
Neuroinflammatory mediators in acquired epilepsy: an update
Yu Chen,Marwa M. Nagib,Nelufar Yasmen,Madison N. Sluter,Taylor L Littlejohn,Ying Yu,Jianxiong Jiang +6 more
Journal ArticleDOI
Metformin and Risk of Malignant Brain Tumors in Patients with Type 2 Diabetes Mellitus
TL;DR: The risk of malignant brain tumors associated with metformin use has rarely been investigated in humans as discussed by the authors, and the authors in this retrospective cohort study investigated such an association in humans.
References
More filters
Journal ArticleDOI
Neuroinflammation: a common pathway in CNS diseases as mediated at the blood-brain barrier.
TL;DR: The blood-brain barrier is an interactive interface that regulates and defines many of the ways that the CNS and the immune system communicate with one another.
Journal ArticleDOI
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
TL;DR: The combination of a PD-1/PD-L1 checkpoint blockade with RT, TMZ, antibodies targeting other inhibitory or stimulatory molecules, targeted therapy, and vaccines may be an appealing solution aimed at achieving optimal clinical benefit in glioblastoma.
Journal ArticleDOI
Heat-shock protein peptide complex–96 vaccination for recurrent glioblastoma: a phase II, single-arm trial
Orin Bloch,Courtney A. Crane,Yelena S. Fuks,Rajwant Kaur,Manish K. Aghi,Mitchel S. Berger,Nicholas Butowski,Susan M. Chang,Jennifer Clarke,Michael W. McDermott,Michael D. Prados,Andrew E. Sloan,Jeffrey N. Bruce,Andrew T. Parsa +13 more
TL;DR: The HSPPC-96 vaccine is safe and warrants further study of efficacy for the treatment of recurrent GBM, and significant pretreatment lymphopenia may impact the outcomes of immunotherapy and deserves additional investigation.
Journal ArticleDOI
Gli activity correlates with tumor grade in platelet-derived growth factor-induced gliomas.
Oren J. Becher,Dolores Hambardzumyan,Elena I. Fomchenko,Hiroyuki Momota,Lori A. Mainwaring,Anne Marie Bleau,Amanda M. Katz,Mark A. Edgar,Anna Marie Kenney,Carlos Cordon-Cardo,Ronald G. Blasberg,Eric C. Holland +11 more
TL;DR: It is found that Gli activation is found in gliomas and correlates with grade, and sonic hedgehog (SHH) is expressed in these tumors and also correlates withgrade, and it is observed that an intact tumor microenvironment or neurosphere conditions in vitro are required for Gli activity.
Journal ArticleDOI
Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma.
TL;DR: Results indicate that COX-2-overexpressing tumors induce a Tr1 response, which is mediated by tumor-exposed, IL-10-enhanced DCs, which may cause DCs to secrete high levels of IL- 10 within the local microenvironment.